Fierce Health Payers June 18, 2021
Even with drug prices skyrocketing and new drugs coming to market at astronomical starting prices, a group of drug companies continues to seek ways to boost profits even higher.
By targeting drug discounts required by the 340B drug pricing program, companies are hurting safety net hospitals, health centers and public health clinics serving the Americans most in need.
In his recent opinion piece, drug industry consultant Jeremy Docken demonstrates how companies are broadening their attacks on 340B. He argues the program has grown too large and needs industry intervention to rein it in, but he omits several important facts.
340B is not your typical government program.
Instead of using taxpayer funding, 340B requires drug companies to discount some of their...
Today's Sponsors
Today's Sponsor